Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EpiCept Corporation

http://www.epicept.com

Latest From EpiCept Corporation

Time To Shop? SK Sees ‘Biggest Opportunity’ For Biotech Investment

At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.

South Korea Deals

Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance

Third-line BRCA-mutated ovarian cancer indication is not a major loss for Rubraca, but Clovis also faces delay in filing to add first-line ovarian cancer therapy to product label.

Clinical Trials Drug Safety

Korean Firms Hunt For Overseas Biologics Manufacturers To Support Growth

Korean companies, including large conglomerates and non-biopharmas, are increasingly jumping into biologics manufacturing through cross-border acquisitions following the successes of Samsung and SK.

South Korea Biologics

Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

Tech Transfer Round-Up Deals
See All

Company Information

  • Other Names / Subsidiaries
    • Maxim Pharmaceuticals
UsernamePublicRestriction

Register